Plain-English translation of NCT07028489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is building a detailed database of patients with newly diagnosed advanced lung cancer who have specific EGFR gene mutations. Researchers will collect standardized health information from you at the start of treatment, during treatment, and when treatment ends. Some participants who haven't yet started osimertinib will also have regular imaging scans to track how the disease responds.
Doctors need better real-world information about how patients with this type of lung cancer respond to different treatment combinations over time. By collecting consistent data from many patients, researchers can better understand which approaches work best and help improve care for future patients.
You likely qualify if…
You likely don't qualify if…
You will enroll in the study before or shortly after starting your lung cancer treatment. Researchers will collect standardized information about your health at the beginning, while you're receiving treatment, and when your treatment ends. If you haven't started osimertinib yet (about 30% of participants), you'll also have imaging scans done at regular intervals to monitor how your cancer is responding.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States